Novartis Animal Health has assumed marketing responsibilities for the joint health supplement Dasuquin in the United Kingdom and Ireland.
Dasuquin is a veterinary formulation developed to deliver advanced cartilage support in dogs. It contains a combination of glucosamine hydrochloride, chondroitin sulphate, avocado/soybean unsaponifiables (ASU), and tea polyphenols. Novartis says these compounds work synergistically to protect the cartilage, thereby playing an important role in supporting and maintaining joint health.
Novartis highlights a 2007 study which, according to the company, demonstrates that the combination of ASU, chondroitin sulphate, and glucosamine hydrochloride delivers incremental benefits compared to the combination of chondroitin sulphate and glucosamine hydrochloride alone.1
Dasuquin is available in flavoured chewable tablets in 80-count containers. Dasuquin is available in two strengths: small-to-medium dogs weighing between 5 and 25 kg and for large dogs weighing over 25 to 50 kg.
Gaynor Hillier, General Manager UK & Ireland Novartis Animal Health said: "This is a fitting addition to our overall orthopaedic health offering for vets and pet owners. Dasuquin brings vets and dog owners advanced joint health support with the next generation of the popular Cosequin family."
Dasuquin is available from Novartis Animal Health in the United Kingdom and Ireland from licensed veterinary wholesalers. For more information on Dasuquin, contact your Novartis Animal Health Territory Manager
Reference:
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.